These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35293331)

  • 21. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Febuxostat in the treatment of gout patients with low serum uric acid level: 1-year finding of efficacy and safety study.
    Shen M; Zhang J; Qian K; Li C; Xu W; Gu B; Wang X; Ren Q; Yang L; Yuan H; Su D; Chen X
    Clin Rheumatol; 2018 Nov; 37(11):3107-3113. PubMed ID: 30196323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
    Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
    Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with recurrent hospital admissions for gout: a case-control study.
    Hutton I; Gamble G; Gow P; Dalbeth N
    J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations in clinical practice guidelines on gout: systematic review and consistency analysis.
    Yu Y; Wang D; Zhou Q; Wang C; Ma X; Gao Y; Song X; Xiao S; Wang Q; Zeng X; Estill J; Qian Z; Chen Y
    Clin Exp Rheumatol; 2020; 38(5):964-972. PubMed ID: 31969230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data.
    Koto R; Nakajima A; Horiuchi H; Yamanaka H
    Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):157-168. PubMed ID: 32939919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
    Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
    Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.
    Li QH; Dai L; Li ZX; Liu HJ; Zou CJ; Ou-Yang X; Lu M; Li T; Li YH; Mo YQ; Schumacher HR
    Clin Rheumatol; 2013 Nov; 32(11):1633-40. PubMed ID: 23857664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
    Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
    Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
    Jatuworapruk K; Satpanich P; Robinson PC; Grainger R
    J Rheumatol; 2023 Apr; 50(4):556-563. PubMed ID: 36379566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a urate lowering regimen in primary gout.
    Bailén R; González Senac NM; López MM; Llena ML; Migoya M; Rodríguez MT; de Miguel E; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):174-80. PubMed ID: 24940666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN).
    Dalbeth N; Bardin T; Doherty M; Lioté F; Richette P; Saag KG; So AK; Stamp LK; Choi HK; Terkeltaub R
    Nat Rev Rheumatol; 2017 Sep; 13(9):561-568. PubMed ID: 28794514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit.
    Roddy E; Packham J; Obrenovic K; Rivett A; Ledingham JM
    Rheumatology (Oxford); 2018 May; 57(5):826-830. PubMed ID: 29447370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Nov; 82(9):763-769. PubMed ID: 37233824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.